Immune Thrombocytopenia
📧 Sign up to get email alerts when something new happens for Immune Thrombocytopenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-29Clinical Trial Update: Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia [Phase 2]
A Phase 2 trial evaluating safety, tolerability, and efficacy of UCB7665 in subjects with primary immune thrombocytopenia has been completed…
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 trial updating teriflunomide for steroid-resistant/relapse immune thrombocytopenia is in progress with unknown status in the listing…
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 trial exploring teriflunomide plus danazol for steroid-resistant/relapsed immune thrombocytopenia is ongoing with unknown status.
-
FDA approval · 2023-11-29FDA Approved: ALVAIZ — Original Application (Teva Pharmaceuticals, Inc.)
ALVAIZ (eltrombopag) from Teva received FDA approval through an original application for the treatment of thrombocytopenia conditions by inc…
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study of Zanubrutinib in Patients With ITP [Phase 2]
Phase 2 trial update of Zanubrutinib in immune thrombocytopenia (ITP) completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-26Clinical Trial Update: High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial [Phase 2]
A Phase 2 randomized trial compares high-dose dexamethasone plus hetrombopag versus high-dose dexamethasone alone as frontline therapy for n…
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia [Phase 3]
Phase 3 trial evaluating subcutaneous belimumab or placebo added to rituximab for persistent or chronic immune thrombocytopenia; currently r…
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP [Phase 3]
Phase 3 trial comparing intravenous immunoglobulin plus prednisone against high-dose dexamethasone for immune thrombocytopenia is currently …
-
CLINICAL_TRIALS trial_result · 2023-08-08Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) [Phase 3]
Phase 3 trial investigating Rozanolixizumab for adult primary immune thrombocytopenia has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2023-08-08Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) [Phase 3]
Phase 3 trial evaluating Rozanolixizumab in adults with persistent or chronic primary immune thrombocytopenia was terminated, with results p…
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP [Phase 2]
A Phase 2 trial evaluating ARGX-113 for safety, efficacy, and pharmacokinetics in adults with primary immune thrombocytopenia has completed.
-
CLINICAL_TRIALS trial_result · 2023-07-12Clinical Trial Update: Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia [Phase 2]
A Phase 2 clinical trial is evaluating low-dose baricitinib combined with high-dose dexamethasone for newly diagnosed immune thrombocytopeni…
-
CLINICAL_TRIALS trial_result · 2023-06-13Clinical Trial Update: Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 clinical trial evaluating low-dose baricitinib plus danazol for steroid-resistant or relapsed immune thrombocytopenia.
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: Immune Thrombocytopenia Management in Adults [Phase 4]
Phase 4 clinical trial update on management strategies for immune thrombocytopenia in adults.
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia [Phase 3]
An extension study of herombopag in pediatric patients with chronic immune thrombocytopenia is being conducted (Phase 3).
-
CLINICAL_TRIALS trial_result · 2023-01-12Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia [Phase 2]
A Phase 2 clinical trial evaluating the efficacy and safety of orelabrutinib in adults with primary immune thrombocytopenia is underway, wit…
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: IVIg Plus Low Dose rhTPO for ITP in Pregnancy [Phase 2]
Phase 2 trial investigating intravenous immunoglobulin plus low-dose recombinant human thrombopoietin for immune thrombocytopenia in pregnan…
-
CLINICAL_TRIALS trial_result · 2022-11-23Clinical Trial Update: Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia [Phase 3]
Phase 3 trial evaluating efficacy and safety of QL0911 in adults with chronic primary immune thrombocytopenia has completed.
-
FDA approval · 2022-11-15FDA Approved: PROMACTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for PROMACTA (eltrombopag olamine) from Novartis, resulting in updated labeling and potential expans…
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate [Phase 3]
Phase 3 trial comparing standard steroid treatment to combined steroid & mycophenolate for newly diagnosed immune thrombocytopenia has compl…
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP) [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of LIV-GAMMA SN Inj.10% for immune thrombocytopenia has completed.
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 clinical trial evaluating baricitinib for steroid-resistant/relapse immune thrombocytopenia (ITP).
-
CLINICAL_TRIALS trial_result · 2022-08-09Clinical Trial Update: The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 trial exploring terbutaline combined with danazol for corticosteroid-resistant or relapsed immune thrombocytopenia.
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]
Phase 2 trial exploring tacrolimus in combination with danazol for steroid-resistant/relapsed immune thrombocytopenia. Status is unknown.
-
CLINICAL_TRIALS trial_result · 2022-07-15Clinical Trial Update: Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia [Phase 2]
Phase 2 trial investigating combined steroid and cyclosporin as first-line treatment for adults with immune thrombocytopenia.